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Abstract
The etiology of pituitary adenomas remains largely unknown, with the exception of involvement of
estrogens in the formation of prolactinomas. We have examined the molecular pathogenesis
of prolactin-producing pituitary adenomas in transgenic female mice expressing the human
choriongonadotropin (hCG) b-subunit. The LH/CG bioactivity is elevated in the mice, with
consequent highly stimulated ovarian progesterone (P4) production, in the face of normal estrogen
secretion. Curiously, despite normal estrogen levels, large prolactinomas developed in these
mice, and we provide here several lines of evidence that the elevated P4 levels are involved in the
growth of these estrogen-dependent tumors. The antiprogestin mifepristone inhibited tumor
growth, and combined postgonadectomy estradiol/P4 treatment was more effective than estrogen
alone in inducing tumor growth. Evidence for direct growth-promoting effect of P4 was obtained
from cultures of primary mouse pituitary cells and rat somatomammotroph GH3 cells. The mouse
tumors and cultured cells revealed stimulation of the cyclin D1/cyclin-dependent kinase
4/retinoblastoma protein/transcription factor E2F1 pathway in the growth response to P4.
If extrapolated to humans, and given the importance of endogenous P4 and synthetic progestins in
female reproductive functions and their pharmacotherapy, it is relevant to revisit the potential role
of these hormones in the origin and growth of prolactinomas.
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Introduction
The prevalence of pituitary adenomas is according to a
recent report 94/100 000 (Daly et al. 2006), and
prolactinomas are by far the commonest form of
pituitary tumors (66%). The incidence of microadeno-
mas in autopsy materials is even higher, 23–27%, and
almost 50% of them stain positively for prolactin
(PRL; McComb et al.1 9 8 3 ). Female sex is a risk factor
for prolactinomas in humans, apparently due to the
effects of estradiol (E2). This link is supported for
example by more common occurrence of these tumors
in women (Faglia 1993, Drange et al. 2000), the
increase of their growth during pregnancy (Molitch
1999), the stimulating effect of estrogens on PRL
secretion (Lieberman et al. 1981, Maurer 1982), and
the occurrence of lactotroph adenomas in transsexual
men during pharmacological estrogen treatment
(Mueller & Gooren 2008). Likewise, several rodent
models support the role of estrogens in the formation
of prolactinomas (Walker & Kurth 1993, Heaney
et al. 2002, Hentges & Low 2002). Estrogens are
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possible ovarian hormones and local growth factors in
this tumorigenesis is less well deﬁned. Although
progesterone (P4) receptors are expressed in mouse
pituitary lactotroph cells (Turgeon et al. 2001) and
human prolactinomas (Jaffrain-Rea et al. 1996),
the role of P4 in pituitary tumorigenesis remains
confusing with reports on both stimulatory and
inhibitory effects in rodents (Poel 1966, Lamberts
et al. 1985).
Recent studies have elucidated the molecular
pathogenesis of pituitary adenomas. Increased acti-
vation of the cyclin D1 (CCND1)/cyclin-dependent
kinase 4 (CDK4)/retinoblastoma protein (RB)/
transcription factor E2F1 pathway, or its suppressed
inhibition due to deﬁciency of p18 and p27, has been
shown to play an important role in mouse models of
pituitary tumors (Jacks et al. 1992, Franklin et al. 1998,
Yamasaki et al. 1998). In humans, tissue-speciﬁc
overexpression of CCND1, or decreased expression of
p16, p18, and p27, is common in tumors of the pituitary
gland (Peters 1994, Musat et al. 2004). Recently,
overexpression of the high-mobility group protein A2
(HMGA2) in pituitary tumors has been described in
mice and men (Fedele et al. 2006). This factor binds to
the inactive RB/E2F1 complex, displacing histone
deacetylase 1 (HDAC1), leading to histone acetylation,
opening of the chromatin structure, and stabilizing
E2F1 (Fedele et al. 2006).
Besides the role of E2 in the pathogenesis of
pituitary tumors (Heaney et al.2 0 0 2 ), E2-induced
proliferation in breast cancer cells activates c-fos,
c-jun, andc-myc(Sutherlandetal.1998,Cicatielloetal.
2004), and in endometrial carcinoma extracellular-
signal-related kinase (ERK)1/2 (Kashima et al. 2009),
leading in both models to upregulation of cyclins D1
and E. Synergism between E2 and P4 action has been
observed in some endocrine tumors. In cultured
post-menopausal, hormonally treated breast tissue,
E2, the synthetic progestin medroxyprogesterone
acetate and their combination increase the number
of Ki-67-positive cells (Eigeliene et al. 2008), with
concomitant increase in CCND1 and p21-positive cells
andreducedp27expression.Whethersimilarsynergism
is possible between E2 and P4 in the pathogenesis of
pituitary adenomas has not been studied.
We have reported previously that transgenic (TG)
female mice with elevated LH/human chorion-
gonadotropin (hCG) action through the expression of
the hCGb-subunit develop lactotroph adenomas in
early adult life, in the face of only a short temporary
peripubertal increase in ovarian E2 production, but
persistently high P4 levels (Rulli et al. 2002). In the
current study, we explore in more detail the role of
the high circulating levels of P4 in these animals in
the growth of the pituitary adenomas and elucidate the
molecular mechanisms involved.
Materials and methods
The transgenic mouse model
TG female mice of the FVB/N strain expressing
heterozygously the hCGb-subunit cDNA, driven by
the human ubiquitin C promoter, and their genotyping
and housing have been described before (Rulli et al.
2002). Non-TG littermates were used as controls.
The animals were handled, and the experiments were
approved in accordance with the local institutional
animal care policies.
Treatments, and blood and tissue collections
In the hormone antagonist study, wild-type (WT) and
TG female mice were subjected to sham operation (C)
or gonadectomy (Gx) at 2 months of age, and thereafter
treated with various combinations of tamoxifen
(Sigma–Aldrich Co.), mifepristone (Sigma–Aldrich),
and bromocriptine (IRA, Sarasota, FL, USA), as
described in Table 1. In the hormone treatment study,
WT and TG females were sham operated or gonad-
ectomized at 2 months of age, and thereafter treated up
to 4.5 months of age with E2 and/or P4, as described
in Table 1.
Following treatments, the mice were killed by
cervical dislocation between 0800 and 1100 h. Blood
was collected by cardiac puncture, and serum was
separated by centrifugation and stored at K70 8C until
analyzed. Pituitary glands were weighed, ﬁxed in 4%
paraformaldehyde or snap-frozen in liquid nitrogen,
and stored at K70 8C until needed.
Hormone measurements
PRL was measured by RIA as described previously
(Bergendahl et al. 1989).
Histological analysis and immunohistochemistry
Paraformaldehyde-ﬁxed pituitaries were cut into
10mm sections and stained with Harris’ hemat-
oxylin–eosin. Immunohistochemistry was carried out
with standard techniques, using commercial mono-
clonal antibodies against mouse Ki-67, and human
CCND1, CDK4, and RB; the sources, dilutions, and
protocols used are described in Supplementary data.
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The density of proliferating cells (DPCs) was
calculated by counting the Ki-67-positive nuclei and
adjusting the result for the measurement area (mm
2),
using the Leica IM 1000, version 1.02 software (Leica
Microsystems AG, Heerbrugg, Switzerland). At least
three samples per group and two sections per sample
were analyzed. From the 12-month-old TG pituitaries
showing macroscopic nodules, proliferation index (PI)
was calculated as the percentage of Ki-67-positive
cells in the nodular area. To this end, samples were
counterstained by hematoxylin, and ten ﬁelds at
40! magniﬁcation were calculated per nodule. The
DPC from the same nodules was also determined.
Quantitative RT-PCR
Total pituitary RNA was extracted by the RNeasy mini
kit (Qiagen) according to the manufacturer’s instruc-
tions. Prior to quantitative RT-PCR (qRT-PCR), all
samples were treated with deoxyribonuclease I
(Invitrogen). Expression levels were determined for
genes presented in Supplementary Table 1, see section
on supplementary data given at the end of this article
(including the primer pairs, annealing temperatures,
and gene bank accession numbers). qRT-PCR analysis
was carried out as described previously (Ahtiainen
et al.2 0 0 5 ). Further details about the methodology and
quality control are presented in Supplementary data.
Primary cell cultures
Primary pituitary cell cultures were performed as
described earlier, with minor modiﬁcations
(Pastorcic et al. 1995). Brieﬂy, 3–5 pituitary glands
of 5-month-old female hCGb-TG mice were enzy-
matically dissociated in PBS containing 1 g/l
D-glucose, 2 g/l collagenase, 1 g/l BSA (Sigma–
Aldrich), and 200 mM ascorbic acid (Merck) and
60!10
3 U/l DNase 1 (Epicentre, Madison, WI,
USA) for 40 min in a shaker at 37 8C, followed by
trituration to disperse the fragments. Cells were plated
in Growth Factor Reduced Matrigel matrix (BD
Biosciences, Bedford, MI, USA)-coated 24-well
plates in DMEM/F12 medium containing penicillin
(50!10
3 U/l) and streptomycin (50 mg/l; Sigma–
Aldrich), 200 mM ascorbic acid, 1 g/l BSA, and 10%
FCS for 24 h. The cells were washed with PBS and
incubated for 24 h in DMEM/F12 medium containing
the antibiotics and 5% dextran-coated charcoal-treated
FCS in the presence of E2,P 4, or both. RNA was
collected immediately after the experiments (RNeasy
mini kit).
Culture of GH3 cells
GH3 cells were cultured in high glucose DMEM
growth medium (Sigma–Aldrich) supplemented with
10% FCS and 1% penicillin/streptomycin (Invitrogen).
Table 1 The treatment schemes with hormone antagonists and hormones
Treatment Abbreviation Gonadectomy (age) Treatment period
Antagonist treatments
Control (no treatment) C – –
Bromocriptine Br – 2–6 months
Mifepristone Mf – 2–6 months
Tamoxifen Tx – 2–6 months
MifepristoneCtamoxifen MfTx – 2–6 months
Short tamoxifen sTx – 7 days–2 months
Short tamoxifenCmifepristone sTxMf – 7 days–2 months (Tx)
2–6 months (Mf)
Gonadectomy Gx 2 months
Hormone treatments
Control (no treatment) C 2 months 2–4.5 months
GxCestradiol GxCE2 2 months 2–4.5 months
GxCprogesterone GxCP4 2 months 2–4.5 months
GxCestradiolCprogesterone GxCE2/P4 2 months 2–4.5 months
Tx was administered as a 1cm long subcutaneous silastic tubes, and progesterone and mifepristone were administered as 2cm long
subcutaneous silastic tubes (inner diameter 1.58 mm/outer diameter 2.41 mm; Dow Corning, Midland, MI, USA) with both ends
sealed with silastic adhesive (Elastocil RTV-1 Silicone Rubber, Wacker-Chemis GmBH, Munich, Germany). Bromocriptine and
estradiol were administered as commercial subcutaneous pellets, and changed every 80–90 days after the initial implantation.
Progesterone was administered in a 1cm subcutaneous silastic tube. The mice in the short tamoxifen and tamoxifenCmifepristone
experiments received tamoxifen by daily injections (10 mg/kg body weight s.c.) between 7 and 21 days, thereafter by silastic tubes
until 2 months. All mice were killed at the end of the treatment periods.
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(10
4 cells/well) in growth medium for 8 h, and then
cultured overnight using medium supplemented with
2% dextran-coated charcoal-stripped FBS and 1%
penicillin/streptomycin.
For the determination of cell proliferation, treat-
ments were performed for 48 h in 2% dextran-coated
charcoal-stripped serum containing medium. Control
cells were treated with vehicle alone, which never
exceeded the ﬁnal concentration of 0.01% (vol/vol).
The steroids were dissolved in either ethanol
(E2 and P4) or dimethyl sulfoxide (mifepristone and
dexamethasone (Sigma–Aldrich)) to a concentration
of 1 mM, and further diluted in medium to the required
concentrations. At the end of the treatment, the
CellTiter 96 Aqueous One Solution Cell Proliferation
Assay (Promega) was performed by adding 20 ml of the
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethonyl-
phenol)-2-(4-sulphenyl)-2H-tetrazolium salt to each
well. The induced color change was measured using
a standard 96-well plate reader at 490 nm. In parallel
wells, cells were counted by the trypan blue
exclusion method.
Statistical analysis
Statistical analyses were performed using the Sigma-
Stat 3.1 software (SPSS Inc., Chicago, IL, USA) or the
SAS System software version 9.1.3 SP2 (SAS Institute,
Gary, NC, USA). One-way ANOVA was used for
multiple comparisons followed by Holm–Sidak’s or
Dunn’s post-hoc tests. Student’s t-test was used to
analyze differences between two groups. Friedman
test, followed by Dunn’s multiple comparison test, was
used to analyze the results of the cell culture
experiments. Statistical analyses of pituitary weights
and PRL levels in the hormone ablation and
replacement experiments were performed by two-way
ANOVA and analysis of covariance. Natural log-
transformation was used when necessary. Residual was
checked for justiﬁcation of the analyses. For corre-
lation analyses, Pearson product moment correlation
was used. For the GH3 cell proliferation experiments,
all statistical tests were performed using GraphPad
Prism 4 statistical software, version 4.01 (GraphPad
Inc., San Diego, CA, USA). Cell proliferation was
compared between treatments using two-way ANOVA
and within treatment using one-way ANOVA,
followed by the post-hoc Bonferroni multiple compari-
son test, where appropriate. All results are presented
as meanGS.E.M.AP value !0.05 was considered
statistically signiﬁcant.
Results
Female hCGb-TG mice develop after puberty
large prolactinomas with high DPCs
As shown before (Rulli et al. 2002), the female TG
mice develop gradually after puberty large multi-
nodular pituitary adenomas, up to 150 mg in weight,
and giving rise to high serum PRL levels, up to a mean
of 10 mg/l (Supplementary Figure 1, see section on
supplementary data given at the end of this article).
At the age of 10–12 months, all TG females have
macroprolactinomas. PRL was the only anterior
pituitary hormone detected by immunohistochemistry
in the tumorous tissue (Supplementary Figure 2, see
section on supplementary data given at the end of this
article). The distribution of Ki-67-positive cells
(Fig. 1) in the pituitary glands indicated a change
from diffuse hyperplasia at 4 months of age to focal
adenomatous growth at 6 months of age, and an
increase with age in the density and proportion (PI; not
shown) of proliferating cells with age (Fig. 1). At 12
months of age, large nodules of macroprolactinomas
were seen with numerous Ki-67-positive cells.
The DPCs in the macroadenomas was higher than in
the rest of the pituitary gland. No metastasis or local
invasion was observed, indicating that the tumors were
not malignant.
WT 6 months
TG 6 months
TG 4 months
TG 12 months
Density of proliferating
cells per mm2
WT 23 ± 5a
TG (4 months) 62 ± 10b
TG (6 months) 84 ± 9b
TG (12 months) 127 ± 15c
Tumor nodules
(12 months)
660 ± 230d
Figure 1 Immunohistochemical evaluation of Ki-67 expression
and density of proliferating cells in the pituitary glands of
wild-type (WT) and transgenic (TG) female mice. Representa-
tive immunohistochemical images of Ki-67 staining are shown
in 6-month-old WT, and 4-, 6-, and 12-month-old TG mouse
samples. The arrowheads indicate Ki-67-positive cells. A large
part of the 12-month-old TG sample comprises a macropro-
lactinoma with numerous Ki-67-positive cells. Scale bars are
100 mm, and the insets are larger magniﬁcations of the same
samples (scale barZ25 mm). Numeric data on density of
proliferating cells/mm
2 in the pituitary glands are presented on
the right side. The WT values are the mean of the 4-, 6-, and
12-month-old mice. Different superscript letters indicate that
these groups differ signiﬁcantly (P!0.05); three to seven mice
were analyzed per group (meanGS.E.M.), and at least two
sections were calculated per specimen. Full colour version of
this ﬁgure available via http://dx.doi.org/10.1677/ERC-10-0016.
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elevated P4 level in the pituitary tumorigenesis
To evaluate the inﬂuence of ovarian hormones on
pituitary growth and PRL levels, WT and TG mice
were ﬁrst subjected to hormone antagonist treatments
(Fig. 2A and B) as described in Table 1. The pituitary
weights and serum PRL levels of WT animals did not
show signiﬁcant responses to any of the antagonist
treatments. Gx of TG mice at 2 months of age
completely abolished both the pituitary growth and
increase in PRL levels observed in intact TG mice
at 6 months of age. The inhibitory effects of tamoxifen
and tamoxifenCmifepristone combination were equal.
Somewhat weaker inhibition was found with bromo-
criptine and mifepristone alone. Short tamoxifen
treatment between 1 week and 2 months of age, to
block the action of the peripubertal E2 peak in TG
females (Rulli et al. 2002), persistently reduced
pituitary weights, and subsequent mifepristone treat-
ment of these mice (2–6 months) showed a trend of a
further decrease (PZ0.08).
The hormone replacement study (Table 1 and
Fig. 2C and D) was shorter (2–4.5 months), and
therefore, the differences between WT and TG mice
were smaller than upon hormone ablation. E2 treatment
increased pituitary weights of Gx WT and TG mice,
but not to the size observed in intact TG females. P4
alone was without effect, but E2CP4 combination
returned the weights in Gx TG mice to levels similar to
intact TG mice. Interestingly, P4 had no effect on PRL
secretion either alone or in combination with E2. This
fact, and the ﬁnding that P4 receptor (Pgr) expression
was increased by E2, but not by P4 (Supplementary
Figure 3D, see section on supplementary data given at
the end of this article), indicated that the P4 effect on
pituitary growth was not due to its conversion to E2.
Ccnd1/Cdk4, E2f1, and Hmga2 are up-regulated,
and RB1 is down-regulated, in the adenomatous
pituitaries
A number of candidate genes with putative involve-
ment in the pituitary adenoma formation, selected on
the basis of literature, were studied by qRT-PCR for
altered expression in the tumors (Supplementary
Table 1). Because intact ovaries were necessary for
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Figure 2 Pituitary weights and serum PRL concentrations in the
WT and TG mice, and their responses to hormonal manipula-
tions in the antagonist treatment (A and B) and hormone
treatment (C and D) experiments, as explained in Table 1.
Pituitary weights (A and C) and serum PRL levels (B and D) of
WT control (open bars) and TG (ﬁlled bars) mice were
measured (meanGS.E.M.; 5–16 mice/group). In A and B, the
data are obtained from 6-month-old mice gonadectomized (Gx)
or sham-operated (C) at 2 months of age, followed by treatment
between 2 and 6 months of age with bromocriptine (Br),
mifepristone (Mf), tamoxifen (Tx), or MfCTx combination.
In addition, one group of mice received short Tx treatment
between 2 weeks and 2 months (sTx; to abolish the peripubertal
E2 peak), and in one group, the latter was followed by a
2–6-month-treatment with Mf (sTxMf). In C and D, the data are
obtained from 4.5-month-old mice with Gx at 2 months of age,
followed by 2.5-month treatments with vehicle (Gx), E2 (GxC
E2), P4 (GxCP4), or their combination (GxCE2P4). For marking
of statistical differences, each bar is provided by superscript
letters. If all letters between two bars are different (e.g. ab and
cd), then they differ signiﬁcantly at P!0.05. If any of the
superscript letters of two bars is the same (e.g. ab and bc), then
there is no statistically signiﬁcant difference between them.
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genes responsive to ovarian hormones (E2 and/or P4),
and/or involved in cell proliferation and/or tumor
promotion, were selected for the screening performed
on samples from 6-month-old WT and TG mice.
The genes with increased expression in TG mice were
subjected to more detailed analysis.
One of the candidate genes, Ccnd1, showed
gradually increased expression with advancing age of
the TG mice, up to 6.1-fold at 12 months of age
(Fig.3A),inlinewiththeconcomitantincreasesinDPC
(Fig. 1) and pituitary weight (Supplementary Figure 1).
Pituitary E2f1 expression reached its maximum in TG
mice at 6 months of age (Fig. 3B), in good agreement
with Ccnd1 expression (rZ0.95). Hmga2 expression
also gradually increased in the TG pituitaries (Fig. 3C).
The CCND1 and CDK4 responses were conﬁrmed
by immunohistochemistry (Fig. 3D). In WT pituitaries,
nuclear CCND1 immunoreactivity was present in
sporadic cells, whereas in 4–6-month-old TG samples,
most cells were prominently stained, and at 12 months,
practically all pituitary cell nuclei were positive.
The intensity of the nuclear staining for CDK4, the
partner of CCND1, followed the same pattern
(Fig. 3D). As an indicator of activity of the CCND1/
CDK4 complex, the immunostaining of the down-
stream effector RB showed an expected reciprocal
decline. At 12 months, most TG pituitary cells were
RB negative, whereas almost all WT cells presented
with positive nuclear RB staining.
The other genes with clearly elevated expression
(greater than threefold) in the pituitary tumors, but not
studied in further detail, included Pttg1, Fgf2, Nupr1,
and Paqr5 (Supplementary Table 1).
Response of pituitary gene expression
to hormone manipulations
We then analyzed the responses of selected genes, with
likely involvement in the tumorigenesis, to Gx and
hormone antagonist treatments (Table 1); the results
are presented in Fig. 4. Gx and all antihormone
treatments reduced the expression of Ccnd1 and E2f1.
The expression of Hmga2, a stabilizer of E2F1 (Fedele
et al. 2006), was suppressed by Gx and mifepristone,
but not by bromocriptine. Pgr expression was
measured because of the putative involvement of P4
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Figure 3 Pituitary expression of Ccnd1, E2f1, Hmga2, CDK4,
and RB in WT and TG female mice. (A–C) depict the levels of
Ccnd1, E2ﬁ, and Hmga2 respectively as measured by qRT-
PCR, in WT (open bars) and TG (ﬁlled bars) mice at 2, 4, 6, and
12 months of age (meanGS.E.M. of 4–6 mice/group). Bars with
different superscript letters differ signiﬁcantly (P!0.05).
(D) Shows representative micrographs of CCND1, CDK4, and
RB immunohistochemistry of WT and TG mice at the ages (mo)
indicated. The arrows indicate nuclei positive for the respective
stainings. Note the weak nuclear staining of CCND1 and CDK4
in WT mice. Similar expression patterns were observed with
CCND1 and CDK4. The bottom row of panels presents RB
expression, which shows strong nuclear staining in WT but
weak in TG mice, especially in older ages. The scale bars are
25 mm in the insets. Full colour version of this ﬁgure available
via http://dx.doi.org/10.1677/ERC-10-0016.
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between the WT and TG females, but was decreased by
Gx and slightly increased by bromocriptine. Galanin is
a marker of lactotrophs and their response to estrogens
(Hyde et al. 1991), and its expression was highly
up-regulated in the TG pituitaries, and dramatically
suppressed by Gx, while the other hormone manipula-
tionshadsmallerdecreasingeffects.Becauseoftheonly
slight 2.1-fold overexpression of bone morphogenic
protein 4 (Bmp4), a known stimulus of prolactinoma
growth (Paez-Pereda et al. 2003), in the TG pituitaries,
we also assessed the expression level of noggin (Nog),
the inhibitor of BMP4 (Supplementary Table 1). Its
expression was highly elevated in the TG pituitaries,
excluding BMP4 as a likely stimulus of the pituitary
tumorigenesis. In the hormone manipulation experi-
ments, the levels of Nog and Gal expression correlated
closely with the pituitary tumor size (not shown). The
short-term treatment with tamoxifen was somewhat
less effective than the other antagonist treatments.
Additional data on serum P4 levels, uterine weights,
Pgr mRNA expression, and pituitary ESR1 and
PGR immunohistochemistry are presented in
Supplementary Figure 3. Responses of the anterior
pituitary hormones (at mRNA level) to the hormonal
manipulations are presented in Supplementary
Figure 4, see section on supplementary data given at
the end of this article.
Effect of E2,P 4, and their combination on primary
mouse pituitary cells and GH3 cells
Finally, to obtain further evidence for a direct P4
effect on pituitary cell proliferation, we stimulated
primary pituitary cells of adult TG females with E2,
P4, and their combination. The concentrations used
(E2Z100 pmol/l and P4Z100 nmol/l) were similar to
those measured in TG female serum (Rulli et al. 2002).
Only the E2CP4 combination, but not either hormone
alone, induced signiﬁcant upregulation of Ccnd1
expression (Fig. 5A).
We then treated rat somatomammotroph GH3 cells
with E2,P 4, and their combinations. When cultured in
the presence of a submaximally stimulating concen-
tration of E2 (100 pM), 0.1 and 1 nM P4 signiﬁcantly
enhanced cell proliferation (Fig. 5B). P4 alone had no
effect up to 1000 nM (Supplementary Figure 6A, see
section on supplementary data given at the end of this
article); neither did it enhance the proliferation effect
of the maximally stimulating E2 concentration of
1 nM. Mifepristone signiﬁcantly reduced the effect
of E2CP4 on cell proliferation, further supporting the
contributory role of P4 in the presence of physiological
E2 levels. When P4 was replaced by dexamethasone, no
additive effect on the cell proliferation stimulated by
E2 was seen (Supplementary Figure 5B, see section on
supplementary data given at the end of this article),
indicating that the P4 effect was unlikely due to the
activation of the glucocorticoid receptor. Moreover,
both Esr1, Esr2,a n dPgr (a and b isoforms)
messages (Supplementary Figure 5D) and PGR protein
(Supplementary Figure 5E) were expressed in the GH3
cells, but neither CYP17 nor CYP19 (Supplementary
Figure 5D). Hence, the P4 effect can be mediated in
GH3 cells through the cognate nuclear receptor, but not
through its conversion to E2. Finally, phosphorylated
forms of ERK and RB proteins were detected in
the GH3 cells by western blots (Supplementary
Figure 5E), indicating that the same signaling
mechanisms as in the pituitary tumors respond to
E2/P4 stimulation in the GH3 cells.
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We observed in this study that the growth of estrogen-
dependent pituitary adenomas in hCG expressing TG
mice is ampliﬁed by P4. This ﬁnding was supported by
P4 effects in cultured primary mouse pituitary cells and
in a rat somatomammotroph cell line. The mechanism
of the tumor promotion in the presence of P4 was found
to involve in the activation of CCND1 and HMGA2,
which are also activated in human pituitary adenomas
(Peters 1994, Fedele et al. 2006). Hence, the molecular
pathogenesis of these murine tumors may have similar
features with that of human pituitary adenomas.
In deciphering the mechanism of the tumor-
promoting effect of high P4 level in the TG mice, it
is important to exclude the possibility that the effect of
P4 is indirect through pituitary or extrapituitary
conversion of P4 to E2, a well-established stimulus of
pituitary adenomas. Several of our ﬁndings support a
direct P4 effect. First, the experiments with GH3 cells,
not able to convert P4 to E2, showed the amplifying
effect of P4 on E2-stimulated cell proliferation.
Secondly, treatment with the P4 (and glucocorticoid)
antagonist mifepristone clearly inhibited the pituitary
growth. Thirdly, in Gx mice, E2CP4 combination was
more effective in inducing pituitary growth than E2
alone. Fourthly, P4 alone had no effect on pituitary
growth, and showed no estrogenic effects, such as
stimulation of PRL secretion or upregulation of
pituitary Pgr expression, thus excluding the conversion
of P4 to functionally meaningful levels of E2.
The role of E2 in the induction of pituitary adenomas
is well known (Heaney et al. 2002), but that of the
other ovarian sex hormone, P4, remains controversial.
While several previous studies demonstrate the
inhibitory effects of P4 on the growth and PRL
production of normal and tumorous pituitary cells
(Haug & Gautvik 1976, Piroli et al. 2001, Rey-Roldan
et al. 2008), there are also studies on stimulatory
effects of this steroid, especially in combination with
E2 (Poel 1966, Chen & Meites 1970, Williams et al.
1994, Yen & Pan 1998). In contrast, ample evidence
shows stimulatory effect of P4, and P4/E2 combination,
on the growth other hormone-responsive tumors, such
as breast and uterine carcinomas (Cicatiello et al. 2004,
Saitoh et al. 2005). The effect observed is intimately
dependent on the cell type, timing and dose of
treatment, and the effect of P4 is often biphasic, with
an acute stimulatory effect followed by loss of the
effect or inhibition. The stimulatory P4 effect may only
occur in the presence of physiological E2levels, but not
on its own, or when the E2 level is supraphysiological.
Additive and synergistic effects of E2 and P4 are well
known on the growth of other hormone-responsive
tumors. In the mammary gland and uterine epithelium,
E2 clearly stimulates cell proliferation, whereas P4 has
both stimulatory and inhibitory effects (Sutherland
et al.1998). In contrast, inuterine stroma, P4stimulates
cell proliferation both in the presence and in the
absence of E2 (Martin et al. 1973). The mitogenic
effect of E2 and P4 in breast cancer cells is mediated
through increased CCND1–Cdk4 activity (Sutherland
et al. 1998, Cicatiello et al. 2004, Saitoh et al. 2005).
Both hormones apparently share the same cascade, but
because E2 upregulates Pgr expression, E2 priming in
fact enhances the P4 response.
Mutations, locally produced growth factors and
hypothalamic endocrine dysregulation, have been
shown to be involved in the pathogenesis of pituitary
adenomas. In our mouse model, the hCG-stimulated
ovarian steroidogenesis apparently provides a mitotic
stimulus to the pituitary gland. Indeed, we found out
that P4 up-regulated in the TG mice, when exposed to
physiological levels of E2, the well-established
tumorigenic CCND1/CDK4/RB/E2F1 signaling
cascade. The same effect of P4 was observed in
cultures of primary mouse pituitary and rat GH3 cells.
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Figure 5 Effects of E2,P 4, and their combinations on cell
proliferation and signaling in primary mouse pituitary cells and
rat somatomammotroph GH3 cells. (A) Expression of Ccnd1
mRNA in primary pituitary cells isolated from 5-month-old TG
mice and stimulated for 24 h as indicated. The results are
meanGS.E.M. of ﬁve individual experiments. Different letters
indicate signiﬁcantdifferences (P!0.05) between the treatment
groups. (B) Effects of 48h P4 stimulation on GH3 cell
proliferation when co-treated with E2 and/or mifepristone (Mf).
The mean cell number in controls was taken as 100%, and
those of the other treatments were related to this ﬁgure
(meanGS.E.M. of 5–6 independent experiments). *P!0.05,
**P!0.01 versus basal plus 100 pM E2;
†P!0.05,
††P!0.01
vs 0.1 nM P4;
‡P!0.05,
‡‡P!0.01 vs 1 nM P4;
§P!0.01 vs 0.1
and 1 nM P4C1000 pM E2C10 mM Mf.
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scription factor Hmga2 was found in the pituitary
adenoma, in keeping with its established involvement
in pituitary tumorigenesis in mice and men (Fedele
et al. 2006). Hence, CCND1 activation, leading to
stimulation of E2F1 expression, seems to occur by
several converging mechanisms in our pituitary
adenomas model. One is decreased RB expression,
which results in E2F1 activation, the other is
upregulation of HMGA2, which displaces HDAC1
from the inactive pRB/E2F1 complex, resulting in
the acetylation and activation of the latter (Fedele
et al. 2006). In addition, we found in GH3 cells
increased RB phosphorylation, which results in
inactivation of this protein and enhanced cyclin D
stimulation of E2F1.
CCND1 is a known target of the MAPK/ERK
signaling pathway, and continued Ccnd1 expression
requires sustained MAPK activation (Lavoie et al.
1996). Cross-talk between ESR1 and PGR has shown
to be mediated through the SRC/P21ras/ERK pathway
in human breast cancer cells (Migliaccio et al. 1998).
Dopamine D2 receptors mediate their inhibitory
signaling through inactivation of ERK1/2 (Liu et al.
2002), explaining why bromocriptine treatment
down-regulated Ccnd1. Tamoxifen, bromocriptine,
and mifepristone treatments also down-regulated
Ccnd1 expression, suggesting that the upregulation of
pituitary Ccnd1 expression in TG females could occur
through cross-talk between normal E2 and high P4
levels, and decreased dopaminergic tone. Similar
responses were observed with the downstream effector
E2f1, in agreement with a recent report that CCND1
can recruit its own promoter through the RB/E2F
pathway after ESR1/PGR activation (Cicatiello et al.
2004). The role of P4 was further conﬁrmed in cultured
primary pituitary cells showing that only the E2/P4
combination induced Ccnd1 expression. This ﬁnding
indicates the importance of cross-talk between E2 and
P4 also in the pituitary gland. Further evidence for the
direct P4 action on pituitary cell proliferation, in
the presence of physiological E2 concentration, was
provided by the GH3 cell culture, in connection with
RB inactivation and ERK activation, both through
P4-stimulated phosphorylation.
A potential weakness of this study is the physio-
logical relevance of the highly elevated hormonal
responses evoked by hCGb expression in these
animals. This in particular concerns the high P4 levels,
about 200 nmol/l vs !10 nmol/l in WT controls, at
the time of onset of tumor growth (19), which are about
an order of magnitude higher than in human luteal
phase. Assuming that the tumorigenic P4 effect is
dose-dependent, the macroprolactinomas in the TG
mice represent responses to a high dose. Smaller, but
still signiﬁcant, tumorigenic effects of P4 are likely to
occur at lower levels that are more relevant to human
physiology. Our results provide a hypothesis for testing
the efﬁcacy of mifepristone as an adjuvant in the
treatment of bromocriptine resistant prolactinomas.
In conclusion, we have demonstrated an amplifying
effect of P4 on the growth of E2-induced pituitary
tumors in female TG mice exposed to high levels of
bioactive LH/hCG. It appears that in the presence
of normal E2 levels, the CCND1/CDK4/RB/E2F1
pathway can be directly enhanced by P4,w i t h
concomitant activation of several oncogenes, including
Hmga2 and E2f1, and downregulation/inactivation of
RB. Taken the importance of P4 in all reproductive
functions of the female, and as a component of
numerous medications (including contraceptive and
hormone replacement therapy regimens), it may be
important to address its potential role in the formation
and treatment of pituitary adenomas.
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